117 related articles for article (PubMed ID: 19955555)
21. Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.
Ganai SA
J Chemother; 2016 Aug; 28(4):247-54. PubMed ID: 27121910
[TBL] [Abstract][Full Text] [Related]
22. Awakening guardian angels: drugging the p53 pathway.
Brown CJ; Lain S; Verma CS; Fersht AR; Lane DP
Nat Rev Cancer; 2009 Dec; 9(12):862-73. PubMed ID: 19935675
[TBL] [Abstract][Full Text] [Related]
23. Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature.
Pi L; Rooprai J; Allan DS; Atkins H; Bredeson C; Fulcher AJ; Ito C; Ramsay T; Shorr ; Stanford WL; Sabloff M; Christou G
Leuk Res; 2019 Nov; 86():106222. PubMed ID: 31522038
[TBL] [Abstract][Full Text] [Related]
24. Targeting p53 by small molecules in hematological malignancies.
Saha MN; Qiu L; Chang H
J Hematol Oncol; 2013 Mar; 6():23. PubMed ID: 23531342
[TBL] [Abstract][Full Text] [Related]
25. Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.
Derenzini E; Rossi A; Treré D
J Hematol Oncol; 2018 May; 11(1):75. PubMed ID: 29855342
[TBL] [Abstract][Full Text] [Related]
26. Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union.
Polsinelli B; Tsigkos S; Naumann-Winter F; Mariz S; Sepodes B
Orphanet J Rare Dis; 2017 Jan; 12(1):17. PubMed ID: 28109318
[TBL] [Abstract][Full Text] [Related]
27. The hypoxia signalling pathway in haematological malignancies.
Irigoyen M; García-Ruiz JC; Berra E
Oncotarget; 2017 May; 8(22):36832-36844. PubMed ID: 28415662
[TBL] [Abstract][Full Text] [Related]
28. Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies.
Cao L; Fan L; Xu W; Li JY
Curr Cancer Drug Targets; 2015; 15(9):769-80. PubMed ID: 26567881
[TBL] [Abstract][Full Text] [Related]
29. The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies.
Zivny J; Klener P; Pytlik R; Andera L
Curr Pharm Des; 2010 Jan; 16(1):11-33. PubMed ID: 20214615
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.
Haas M; Lonial S
Expert Opin Investig Drugs; 2005 Sep; 14(9):1161-9. PubMed ID: 16144500
[TBL] [Abstract][Full Text] [Related]
31. Urinary trypsin inhibitor levels in the urine of patients with haematological malignancies.
Takubo T; Kumura T; Nakamae H; Aoyama Y; Koh KR; Ohta K; Yamane T; Hino M; Kanashima H; Kamitani T; Ohta T; Kuwajima S; Tatsumi N
Haematologia (Budap); 2001; 31(3):267-72. PubMed ID: 11855791
[TBL] [Abstract][Full Text] [Related]
32. Protein phosphatase, Mg
Husby S; Hjermind Justesen E; Grønbæk K
Br J Haematol; 2021 Feb; 192(4):697-705. PubMed ID: 33616916
[TBL] [Abstract][Full Text] [Related]
33. Hippo pathway deregulation: implications in the pathogenesis of haematological malignancies.
Cacemiro MC; Berzoti-Coelho MG; Cominal JG; Burin SM; Castro FA
J Clin Pathol; 2017 Jan; 70(1):9-14. PubMed ID: 27798082
[TBL] [Abstract][Full Text] [Related]
34. Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies.
Mynott RL; Habib A; Best OG; Wallington-Gates CT
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108836
[TBL] [Abstract][Full Text] [Related]
35. The diagnosis, prognosis, and therapeutic application of MicroRNAs in haematological malignancies.
Li X; Zhong H
Hematology; 2016 Jun; 21(5):263-71. PubMed ID: 26907667
[TBL] [Abstract][Full Text] [Related]
36. Advances in the treatment for haematological malignancies.
Piccaluga PP; Martinelli G; Baccarani M
Expert Opin Pharmacother; 2006 Apr; 7(6):721-32. PubMed ID: 16556088
[TBL] [Abstract][Full Text] [Related]
37. What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.
Williams AM; Zent CS; Janelsins MC
Br J Haematol; 2016 Sep; 174(6):835-46. PubMed ID: 27391367
[TBL] [Abstract][Full Text] [Related]
38. Thromboembolic complications in malignant haematological disorders.
Castelli R; Ferrari B; Cortelezzi A; Guariglia A
Curr Vasc Pharmacol; 2010 Jul; 8(4):482-94. PubMed ID: 19485900
[TBL] [Abstract][Full Text] [Related]
39. Melatonin: does it have utility in the treatment of haematological neoplasms?
Li T; Yang Z; Jiang S; Di W; Ma Z; Hu W; Chen F; Reiter RJ; Yang Y
Br J Pharmacol; 2018 Aug; 175(16):3251-3262. PubMed ID: 28880375
[TBL] [Abstract][Full Text] [Related]
40. Targeting Hedgehog in haematological malignancies.
Ghia P
Lancet Haematol; 2015 Aug; 2(8):e311-2. PubMed ID: 26688482
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
